Dostarlimab-gxly
Dostarlimab-gxly is a type of drug called an immune checkpoint inhibitor (a type of immunotherapy). It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. It works by keeping cancer cells from suppressing the immune system. This allows the immune system to attack and kill the cancer cells.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Dostarlimab-gxly is approved to treat adults with:
- Endometrial cancer that has spread outside the uterus or come back. It is used:
- With carboplatin and paclitaxel and then alone in patients whose cancer is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H).
- Alone in patients whose cancer is dMMR, cannot be treated with surgery or radiation therapy, and got worse during or after treatment with platinum chemotherapy.
- Solid tumors that are dMMR, have spread or come back, and got worse during or after other treatment and cannot be treated with other therapies.¹
¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that dostarlimab-gxly provides a clinical benefit in these patients.
Dostarlimab-gxly is also being studied in the treatment of other types of cancer.
More About Dostarlimab-gxly
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Dostarlimab-gxly - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
A Better Biomarker for Cancer Immunotherapy?
Immunotherapy’s Role in Treating Endometrial Cancer Expected to Grow
Immunotherapy and… Nothing Else? Studies Test Potential Paradigm Shift in Cancer Treatment
Cancer Immunotherapies Don’t Work for Everyone: HLA Gene May Explain Why
Clinical Trials Accepting Patients
Find Clinical Trials for Dostarlimab-gxly - Check for trials from NCI's list of cancer clinical trials now accepting patients.